GEN Exclusives

More »

GEN News Highlights

More »
Nov 17, 2008

Midatech Forms Nanotech-Focused Subsidiary

  • Midatech Group has formed a new drug development subsidiary, PharMida. Formation of this Basel-based unit follows an investment by a group of Switzerland-based private investors into Midatech. PharMida will be headed by Fritz R. Buhler, M.D., as chairman and Jan Mous, Ph.D., as CEO.

    The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage a collection of already existing and promising Midatech products or product lines.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »